Accumulation of 123I-Ioflupane Is a Useful Marker of the Efficacy of Selegiline Monotherapy in Drug-Naïve Parkinson’s Disease

Accumulation of 123I-Ioflupane Is a Useful Marker of the Efficacy of Selegiline Monotherapy in Drug-Naïve Parkinson’s Disease

Background: Selegiline enhances the patient’s endogenous dopamine by inhibiting dopamine metabolism. The efficacy of selegiline monotherapy for drug-naïve Parkinson’s disease (PD) patients may depend on the degree of dopaminergic neuronal degeneration. 123I-Ioflupane single photon emission computed...

Full description

Bibliographic Details
Main Authors: Hidetomo Murakami, Tetsuhito Nohara, Masanobu Uchiyama, Yoshiyuki Owan, Akinori Futamura, Azusa Shiromaru, Setsuro Tsukada, Yu Saito, Takeshi Kuroda, Satoshi Yano, Seiichiro Ishigaki, Hirotaka Katoh, Jiro Munechika, Yoshimitsu Ohgiya, Takehiko Gokan, Kenjiro Ono
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-09-01
Series:Frontiers in Aging Neuroscience
Subjects:
Parkinson disease
selegiline monotherapy
monoamine oxidase inhibitor
123I-Ioflupane SPECT
123I-MIBG myocardial scintigraphy
Online Access:http://journal.frontiersin.org/article/10.3389/fnagi.2017.00321/full

Internet

http://journal.frontiersin.org/article/10.3389/fnagi.2017.00321/full

Similar Items